Pharmaceutical companies will invest 21 billion Mexican pesos to strengthen the domestic production of medicines as part of the federal Plan México [1].
This initiative represents a strategic shift toward pharmaceutical sovereignty. By reducing reliance on foreign imports, Mexico aims to secure its medical supply chain and ensure that essential drugs remain available to the public regardless of global market fluctuations.
David Kershenobich Stalnikowitz, the head of the Secretariat of Health (SSa), said the investment was announced [1]. The funding comes from a consortium of pharmaceutical firms, including Abbott, Bristol-Myers Squibb, Neolpharma, and Opella México [1].
The primary goal of the investment is to guarantee the national production of medicines [2]. This effort is designed to improve direct access to drugs for citizens by streamlining the path from manufacturing to the patient [3].
The Plan México framework coordinates these private investments with government health priorities. By incentivizing companies to build or expand facilities within the country, the administration seeks to foster a more resilient healthcare infrastructure [2].
Officials said the move will strengthen the overall pharmaceutical industry [3]. This includes not only the increase in production volume, but also the development of local technical expertise in drug manufacturing [1].
The 21 billion peso commitment [1] marks a significant financial injection into the sector. This scale of investment is intended to create a sustainable ecosystem where the government and private sector collaborate to prevent drug shortages [2].
“Pharmaceutical companies will invest 21 billion Mexican pesos to strengthen the domestic production of medicines”
This investment signals Mexico's intent to transition from a consumer of imported pharmaceuticals to a regional production hub. By integrating private capital from global firms like Abbott and Bristol-Myers Squibb into the state-led Plan México, the government is attempting to mitigate the risks of supply chain disruptions that have historically led to medication shortages in the public health system.
